Cartesian Therapeutics
Clinical trials sponsored by Cartesian Therapeutics, explained in plain language.
A clinical-stage biotech developing RNA cell therapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Engineered immune cells take aim at myasthenia gravis
Disease control OngoingThis Phase 2 trial is testing an experimental therapy called Descartes-08 for people with generalized myasthenia gravis, a condition that causes muscle weakness. Descartes-08 uses a patient's own immune cells, engineered to target and potentially reduce the harmful immune cells t…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take on lupus in tiny trial
Disease control OngoingThis Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC